Last reviewed 2026-04-20 · How we verify

Climbazol (CLIMBAZOLE)

Phase 2 active Small molecule

Climbazol (generic name: CLIMBAZOLE) is a drug. It is currently in Phase 2 development for Seborrheic dermatitis.

Climbazol works by blocking the action of an enzyme called Cytochrome P450 3A4.

Climbazol is a small molecule modality targeting Cytochrome P450 3A4, used to treat Seborrheic dermatitis. Its commercial status is unknown, and it is not FDA approved. Climbazol works by inhibiting the activity of Cytochrome P450 3A4, a key enzyme involved in the metabolism of various drugs. The exact mechanism of action in treating Seborrheic dermatitis is not well understood. Further research is needed to determine its efficacy and safety.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLIMBAZOLE
Target	Cytochrome P450 3A4
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of your body like a factory with many machines working together. Cytochrome P450 3A4 is like a key machine that helps break down certain medicines. Climbazol is like a special tool that blocks this machine, which can affect how your body processes these medicines.

Approved indications

Seborrheic dermatitis

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Climbazol CI brief — competitive landscape report
Climbazol updates RSS · CI watch RSS

Frequently asked questions about Climbazol

What is Climbazol?

Climbazol (CLIMBAZOLE) is a Small molecule drug, indicated for Seborrheic dermatitis.

How does Climbazol work?

Climbazol works by blocking the action of an enzyme called Cytochrome P450 3A4.

What is Climbazol used for?

Climbazol is indicated for Seborrheic dermatitis.

What is the generic name of Climbazol?

CLIMBAZOLE is the generic (nonproprietary) name of Climbazol.

What development phase is Climbazol in?

Climbazol is in Phase 2.

What does Climbazol target?

Climbazol targets Cytochrome P450 3A4.

Target: All drugs targeting Cytochrome P450 3A4
Therapeutic area: All drugs in Metabolic
Indication: Drugs for Seborrheic dermatitis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing